|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.02 EUR | +2.64% |
|
+3.23% | -40.48% |
| 12-06 | Bayer: new €5 billion credit line | CF |
| 12-06 | Bayer Secures New EUR5 Billion Revolving Credit Facility | MT |
| Capitalization | 19.66B 20.78B 18.23B 16.3B 29.38B 1,760B 32.52B 227B 83.85B 723B 78.06B 76.32B 3,115B | P/E ratio 2024 * |
-723x | P/E ratio 2025 * | 8.43x |
|---|---|---|---|---|---|
| Enterprise value | 51.97B 54.92B 48.18B 43.09B 77.65B 4,651B 85.96B 599B 222B 1,911B 206B 202B 8,234B | EV / Sales 2024 * |
1.12x | EV / Sales 2025 * | 1.05x |
| Free-Float |
100% | Yield 2024 * |
0.54% | Yield 2025 * | 0.54% |
More valuation ratios
* Estimated data
More news
Last Transcript: Bayer AG
More press releases
More news
| 1 day | +2.64% | ||
| 1 week | +3.35% | ||
| Current month | +3.23% | ||
| 1 month | -18.57% | ||
| 3 months | -30.92% | ||
| 6 months | -30.01% | ||
| Current year | -40.48% |
1 week
18.93
20.30
1 month
18.4124.76
Current year
18.4136.09
1 year
18.4136.09
3 years
18.4167.99
5 years
18.4178.34
10 years
18.41146.45
| Director | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 58 | 2023-05-31 |
| Director of Finance/CFO | 55 | 2018-05-31 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 57 | 2021-01-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 68 | 2002-03-31 |
André van Broich
BRD | Director/Board Member | 54 | 2012-03-31 |
| Director/Board Member | 65 | 2022-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | ||
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | +62.98% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +2.64% | +3.35% | -36.87% | -54.77% | 20.25B | ||
| +0.13% | +4.89% | +40.56% | +236.64% | 743B | ||
| +1.88% | +5.07% | +14.32% | +123.06% | 484B | ||
| -0.14% | -3.92% | -5.83% | -6.32% | 360B | ||
| +0.01% | -3.76% | +21.87% | +48.25% | 311B | ||
| -0.44% | -0.03% | -2.96% | +40.56% | 262B | ||
| +0.27% | +1.22% | +2.41% | -29.05% | 234B | ||
| +0.34% | +0.57% | +5.03% | +30.07% | 210B | ||
| -0.63% | -3.82% | +5.58% | +22.07% | 206B | ||
| -0.64% | -2.67% | +0.63% | +34.65% | 147B | ||
| Average | +0.47% | -0.12% | +4.48% | +44.51% | 297.75B | |
| Weighted average by Cap. | +0.36% | +0.72% | +14.49% | +89.62% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 46.4B 49.04B 43.02B 38.47B 69.33B 4,153B 76.75B 535B 198B 1,706B 184B 180B 7,352B | 46.58B 49.22B 43.18B 38.62B 69.59B 4,169B 77.04B 537B 199B 1,713B 185B 181B 7,380B |
| Net income | -25.93M -27.4M -24.04M -21.5M -38.74M -2.32B -42.89M -299M -111M -954M -103M -101M -4.11B | 2.33B 2.47B 2.16B 1.94B 3.49B 209B 3.86B 26.92B 9.95B 85.83B 9.27B 9.06B 370B |
| Net Debt | 32.31B 34.14B 29.95B 26.79B 48.27B 2,892B 53.44B 373B 138B 1,188B 128B 125B 5,119B | 29.31B 30.97B 27.17B 24.3B 43.79B 2,623B 48.47B 338B 125B 1,078B 116B 114B 4,643B |
More financial data
* Estimated data
Employees
94,245
Sector
Pharmaceuticals
Calendar
2025-03-05
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-06 | 20.02 € | +2.64% | 4,615,729 |
| 24-12-05 | 19.50 € | +1.25% | 3,354,823 |
| 24-12-04 | 19.26 € | +0.14% | 3,193,159 |
| 24-12-03 | 19.23 € | -0.27% | 2,918,759 |
| 24-12-02 | 19.29 € | -0.53% | 4,490,618 |
Delayed Quote Xetra, December 06, 2024 at 11:39 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
20.02EUR
Average target price
28.00EUR
Spread / Average Target
+39.92%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition